NCT05707832 - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

July 30, 2024

Study Completion Date

March 31, 2025

Conditions

Invasive CandidiasisInvasive Aspergillosis

Interventions

DRUG

Amphotericin B cholesteryl Sulfate Complex for Injection

Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin